Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+ - NCT03057860Recruiting
Registry study for moderate to severe atopic dermatitis in Germany
This study is a national registry that collects information from people with moderate-to-severe atopic dermatitis (eczema). It helps doctors understand what treatments are used and how patients are doing over time.
Hanover, Lower SaxonyAges Any age - NCT05098821Recruiting
Study factors that affect eczema control on dupilumab
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
BerlinAges 18–75 - NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Birmingham, AlabamaAges 12 years+ - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Phoenix, ArizonaAges 12 years+ - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT06158490Enrolling by invitationPhase 2
JYP0061 tablet for moderate to severe eczema
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07259343Recruiting
Cream with milk peptide for children's mild eczema
This trial tests if a special cream made with a milk protein peptide can improve mild eczema symptoms like itching and reduce bacteria on the skin in children aged 2 to 12.
Aguascalientes, AguascalientesAges 2–12 - NCT07073677RecruitingPhase 2
Testing a new eczema ointment for mild to moderate cases
This study tests a new ointment called IN-115314 for adults with mild to moderate eczema. Researchers want to see if it helps control symptoms like itching and redness better than a placebo, and check that it's safe to use.
Ansan, ALLAges 19 years+ - NCT07560618RecruitingPhase 4
Testing a new cream for itch relief in atopic dermatitis
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Sacramento, CaliforniaAges 12 years+ - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06238765Recruiting
Adolescent Eczema Drug Safety Registry
This registry tracks the safety and effectiveness of medications used for moderate to severe atopic dermatitis (eczema) in adolescents aged 10 to 15. It helps doctors understand how well these treatments work and what side effects might occur over time.
Waltham, MassachusettsAges 10–15 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Birmingham, AlabamaAges 12 years+ - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+ - NCT06300697Recruiting
Food allergy and eczema study at University of Michigan
This study looks at how food allergies and eczema (atopic dermatitis) are related. You will have an oral food challenge (eating a small amount of a possible allergen in a safe setting) and give blood and skin samples to help researchers learn more.
Ann Arbor, MichiganAges 10–55 - NCT03976622Enrolling by invitation
Inflammation study in vitiligo and other skin conditions
This study looks at inflammation in people with vitiligo, psoriasis, atopic dermatitis, or alopecia areata. It aims to understand how these conditions compare, which may lead to better treatments.
Bordeaux, BordeauxAges 18–75 - NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
BolognaAges 6 months–17 years - NCT07242638RecruitingPhase 2
Abrocitinib for skin and hair loss in Down syndrome
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
New York, New YorkAges 12 years+ - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT04504955Recruiting
Atopic dermatitis patient registry for medication safety and results
This study is a real-world registry that collects information from adults with atopic dermatitis (eczema) to track how newly started treatments work and how safe they are over time. It may help researchers and doctors better understand medication effects in everyday care.
Waltham, MassachusettsAges 18 years+
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 175 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.